Shots:

• Novavax will supply ~60M doses of its COVID-19 vaccine to the UK government for P-III study evaluating the efficacy of NVX-CoV2373 in ~9-000 adults aged 18-85yrs. in the UK. The trial is expected to initiate in Q3’20
• Novavax will expand its collaboration with FUJIFILM Diosynth- which will manufacture the antigen component of NVX-CoV2373 from its Billingham- Stockton-on-Tees site in the UK- in addition to its sites in NC and Texas in the US
• The FUJIFILM Diosynth site in the UK is expected to produce up to 180M doses annually- which boosts the global supply of NVX-CoV2373 for additional markets. NVX‑CoV2373 elicited robust Ab responses superior to seen in human convalescent sera in P-I/II clinical study while P-II study is expected to begin in Aug’2020

 Ref: Novavax | Image: Reuters